CytoDyn Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Changes in Shareholders' Equity (Deficit)

Consolidated Statement of Changes in Shareholders' Equity (Deficit) - USD ($)	Total	Private Equity Offering One	Private Equity Offering Two	Conversion Features One	Conversion Features Two	Conversion Features three	Exercise Price 1	Exercise Price 2	Conversion Features Four	Conversion Features Five	Conversion Features Six	Conversion Features Seven	Preferred Stock	Common Stock	Common Stock Private Equity Offering One	Common Stock Private Equity Offering Two	Common Stock Conversion Features One	Common Stock Conversion Features Two	Common Stock Conversion Features three	Common Stock Exercise Price 1	Common Stock Exercise Price 2	Common Stock Conversion Features Four	Common Stock Conversion Features Five	Common Stock Conversion Features Seven	Additional Paid-in Capital	Additional Paid-in Capital Private Equity Offering One	Additional Paid-in Capital Private Equity Offering Two	Additional Paid-in Capital Conversion Features One	Additional Paid-in Capital Conversion Features Two	Additional Paid-in Capital Conversion Features three	Additional Paid-in Capital Exercise Price 1	Additional Paid-in Capital Exercise Price 2	Additional Paid-in Capital Conversion Features Four	Additional Paid-in Capital Conversion Features Five	Additional Paid-in Capital Conversion Features Six	Additional Paid-in Capital Conversion Features Seven	Rescission Amount	Accumulated Deficit
Beginning balance at May. 31, 2014	$ 3,922,232												$ 95	$ 55,753											$ 50,678,616												$ (378,000)	$ (46,434,232)
Beginning balance, shares at May. 31, 2014													95,100	55,753,311
Rescission expirations and exclusions	378,000																																				$ 378,000
Amortization of deferred offering costs related to rescission liability	(68,292)																								(68,292)
Common shares issued to extinguish promissory notes payable, convertible debt and related interest, shares																	104,153	5,628,330	119,580
OID, intrinsic value related to warrants	2,505,261																								2,505,261
Common shares issued to extinguish promissory notes payable, convertible debt and related interest, value				$ 52,077	$ 4,221,250	$ 86,296											$ 104	$ 5,628	$ 120									$ 51,973	$ 4,215,622	$ 86,176
Exercise of common stock warrants, shares																				1,938,974	100,000
Exercise of common stock warrants, Value							$ 1,066,435	$ 75,000												$ 1,939	$ 100										$ 1,064,496	$ 74,900
Stock-based compensation	631,302																								631,302
Inducement interest on note conversions and warrant exercises	555,626																								555,626
Inducement interest on reissued warrants	970,367																								970,367
Net (loss) at year ended	(25,088,070)																																					(25,088,070)
Ending balance at May. 31, 2015	(10,692,516)												$ 95	$ 63,644											60,766,047													(71,522,302)
Ending balance, shares at May. 31, 2015													95,100	63,644,348
Debt discount due to reduction in note conversion price from ($0.75 to $0.675/share)	329,524																								329,524
Common shares issued to extinguish promissory notes payable, convertible debt and related interest, shares																						4,095,008	792,201
Common shares issued to extinguish promissory notes payable, convertible debt and related interest, value									$ 2,764,154	$ 594,152												$ 4,095	$ 792										$ 2,760,059	$ 593,360
Conversion of convertible debt and extinguishment of derivative liability, Value												$ 4,732,514												$ 5,275												$ 4,727,239
Conversion of convertible debt and extinguishment of derivative liability, shares																								$ 5,274,656
Exercise of common stock warrants (cashless), shares														74,490
Exercise of common stock warrants (cashless), value														$ 74											(74)
Exercise of common stock warrants, shares																				192,307	603,286
Exercise of common stock warrants, Value							$ 96,154	$ 452,465												$ 192	$ 604										$ 95,962	$ 451,861
Stock-based compensation	2,353,194																								2,353,194
Proceeds from private equity offering, shares															44,357,838	4,301,500
Inducement interest on reissued warrants											$ 757,871																								$ 757,871
Proceeds from private equity offering, value		$ 33,268,464	$ 4,301,500												$ 44,358	$ 4,302										$ 33,224,106	$ 4,297,198
Deferred offering costs	(3,915,127)																								(3,915,127)
Modification of warrants related to conversion inducement											$ 866,713																								$ 866,713
Net (loss) at year ended	(25,703,612)																																					(25,703,612)
Ending balance at May. 31, 2016	$ 10,205,450												$ 95	$ 123,336											$ 107,307,933													$ (97,225,914)
Ending balance, shares at May. 31, 2016													95,100	123,335,634